Apotex, Teva Pharmaceuticals, Aurobindo Pharma and Glenmark Pharmaceuticals may now market and sell their generic versions of the drug to both children and adults.
“Today’s approvals mark an important step forward in bringing consumers additional treatments that have met the FDA’s rigorous standards,” Kathleen Uhl, MD, director of the agency’s Office of Generic Drugs, said in a news release. “Quickly bringing generics to market so patients have more options to treat their conditions is a top priority for the FDA.”
More articles on supply chain:
Pharma spent $78M on lobbying so far this year: 4 statistics
Mallinckrodt considers sale of generic drug unit: 4 things to know
Medicare patients don’t see benefits of drug rebates, says researchers
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
